

EMA/719217/2014

European Medicines Agency decision

P/0320/2014

of 19 December 2014

on the acceptance of a modification of an agreed paediatric investigation plan for pollen from *Phleum pratense* (EMA-000848-PIP01-10-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0320/2014

of 19 December 2014

on the acceptance of a modification of an agreed paediatric investigation plan for pollen from *Phleum pratense* (EMA-000848-PIP01-10-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/296/2010 issued on 22 December 2010,

Having regard to the application submitted by ALK-Abelló A/S on 19 August 2014 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 14 November 2014, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for pollen from *Phleum pratense*, suspension for injection, subcutaneous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to ALK-Abelló A/S, Bøge Allé 6-8, 2970 - Hørsholm, Denmark.

Done at London, 19 December 2014

For the European Medicines Agency
Zaide Frias
Head of Division (ad interim)
Human Medicines Research and Development Support
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/529176/2014

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA-000848-PIP01-10-M01

Scope of the application

Active substance(s):

Pollen from Phleum pratense

Condition(s):

Treatment of allergic rhinitis / rhino-conjunctivitis

Pharmaceutical form(s):

Suspension for injection

Route(s) of administration:

Subcutaneous use

Name / corporate name of the PIP applicant:

ALK-Abelló A/S

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, ALK-Abelló A/S submitted to the European Medicines Agency on 19 August 2014 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/296/2010 issued on 22 December 2010.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 16 September 2014.

Scope of the modification

Some measures or timelines of the Paediatric Investigation Plan have been modified.



Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 14 November 2014

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of allergic rhinitis / rhino-conjunctivitis

The waiver applies to:

- all subsets of the paediatric population from birth to 5 years of age;
- for suspension for injection subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric Investigation Plan

2.1. Condition

Treatment of allergic rhinitis / rhino-conjunctivitis

2.1.1. Indication(s) targeted by the PIP

Treatment of allergic rhinitis in patients with grass pollen allergy with or without mild to moderate allergic asthma

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

Children from 5 to less than 18 years old

2.1.3. Pharmaceutical form(s)

Suspension for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	0	Not applicable.
Clinical studies	1	Study 1: Avanz Phleum Pratense paediatric trial Double blind, randomised, multicentre, multiple dose, placebo controlled, parallel-group trial to evaluate the long-term efficacy and safety of Avanz Phleum Pratense compared to placebo in children with allergic rhinitis symptoms and rescue medication usage due to Phleum pratense pollen.

Area	Number of measures	Description
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By September 2024
Deferral for one or more studies contained in the paediatric investigation plan:	Yes